A randomised clinical trial investigating the effect of everolimus versus sunitinib in patients with metastatic renal cell carcinoma
Studied treatment | everolimus |
Control treatment | sunitinib |
Patients | patients with metastatic renal cell carcinoma |
Group sizes | 238 / 233 |
treatment line | line 1 |
Blindness | Inclusion period | ||
Follow-up duration | Centers | ||
Lost to FU | geographical localisation | ||
Primary endpoint | Design | Cross over | |
Hypothese | Non inferiority |
Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765-72 [PMID: 25049330] link to pdf add to Mendeley
ClinicalTrial.gov record NCT00903175
Appears in following systematic reviews: